Skip Navigation
United States Flag

An official website of the United States government. Here's how you know >

A New Look for HHS-OIG. Learn More >>

Change Font Size

Audit (A-04-09-06103)

Review of Medicare Outpatient Payments for Oxaliplatin in Virginia

Executive Summary

For all 57 Medicare outpatient payments reviewed, seven hospitals billed National Government Services (NGS), a Medicare fiscal intermediary, for the incorrect number of service units of oxaliplatin. Oxaliplatin is a chemotherapy drug used to treat colorectal cancer. As a result of the incorrect billing, the hospitals received overpayments totaling $1.4 million during calendar year 2005. These overpayments occurred primarily because the hospitals did not update their systems following a change in Medicare billing guidance.

We recommended that NGS recover the $1.4 million in overpayments to the hospitals. NGS agreed with our recommendation.

Complete Report

Download the complete report (PDF)

Adobe® Acrobat® is required to read PDF files.

Copies can also be obtained by contacting the Office of Public Affairs at 202-619-1343.

Office of Inspector General, U.S. Department of Health and Human Services | 330 Independence Avenue, SW, Washington, DC 20201